Skip to content

Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022

Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05595252
Enrollment
100
Registered
2022-10-26
Start date
2014-01-01
Completion date
2022-12-31
Last updated
2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Intraepithelial Neoplasia

Brief summary

In France, the screening rate for cervical cancer remains too low. Screening is simple and non-invasive. Pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is the first encounter with a gynecologist. The cervical smear is therefore an important step of the first consultation during pregnancy In the case of pathological results, colposcopies with biopsies are performed, frequently finding CIN 1 to 3. (cervical intraepithelial neoplasia) These CIN lesions evolve slowly and most of the time, treatment can be withheld until the end of the pregnancy. Several studies suggest a higher regression rate in pregnant patients. Our study will evaluate the rate of regression, progression or persistence of these lesions in per and post partum patients in Nancy, between 2014 and 2022. To obtain our results, we will compare the results of per and post partum biopsies in each patient. In a second step, we will study the risk factors of aggravation or on the contrary the protective factors, allowing a faster regression of the lesions

Interventions

BIOLOGICALcervical biopsy

cervical biopsy made during and after pregancy

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* women who have a CIN lesion during pregnancy * in Nancy, France, MRUN Center * between 2014 and 2022

Exclusion criteria

* lost of follow up women

Design outcomes

Primary

MeasureTime frameDescription
progress, persistence or regression of CIN lesion countup to one year after deliverycervical biopsy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026